Cyclooxygenase-2: A therapeutic target

Annual Review of Medicine

Volumn 53, Issue , 2002, Pages 35-57

  Turini, Marco E ^a   DuBois, Raymond N ^a  

^a NESTLÉ RESEARCH CENTER   (Switzerland)

Author keywords

Biology; Cyclooxygenase; Disease; Inflammation; Prostaglandins

Indexed keywords

ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN;

ADENOMATOUS POLYP; ALZHEIMER DISEASE; ANGIOGENESIS; ARACHIDONIC ACID METABOLISM; ARTHRITIS; CANCER; ENTERITIS; ENZYME INHIBITION; FAMILIAL POLYPOSIS; HUMAN; INFLAMMATION; KIDNEY FUNCTION; PRIORITY JOURNAL; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; INFLAMMATION; ISOENZYMES; MEMBRANE PROTEINS; NEOPLASMS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0036177671     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.53.082901.103952     Document Type: Review

References (153)

1. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
2. Renal toxicity of the nonsteroidal anti-inflammatory drugs
3. Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine
4. Cyclooxygenases: Structural, cellular, and molecular biology
5. Prostanoid receptors: Structures, properties, and functions
6. Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2
7. Prostaglandin endoperoxide synthase gene structure: Identification of the transcriptional start site and 5′-flanking regulatory sequences
8. Prostaglandin endoperoxide synthases-1 and -2
9. Prostaglandin synthase 2
10. Regulation of fibroblast cyclooxygenase synthesis by interleukin-1
11. In vivo and in vitro expression of a non-mammalian cyclooxygenase-1
12. Prostaglandin endoperoxide H synthases (cyclooxygenases)- 1 and 2
13. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia
14. Prostaglandin H synthase-2 is expressed abnormally in human colon cancer: Evidence for a transcriptional effect
15. 2 and distal prostaglandin synthase 1
16. Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells
17. The biosynthesis and metabolism of prostaglandins
18. The discovery and function of COX-2
19. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis
20. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage: Influence of nitric oxide
21. Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis
22. COX-1 and COX-2 tissue expression: Implications and predictions
23. Nitric oxide synthase/COX cross-talk: Nitric oxide activates COX-1 but inhibits COX-2-derived prostaglandin production
24. Nitric oxide enhances cyclooxygenase activity in articular cartilage
25. Selective inhibition of inducible nitric oxide synthase in experimental osteoarthritis is associated with reduction in tissue levels of catabolic factors
26. Regulation of prostaglandin biosynthesis by nitric oxide is revealed by targeted deletion of inducible nitric-oxide synthase
27. Synthesis and biological evaluation of the 1,5-diarylpyrazol class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3 (trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide (SC-58635, celecoxib)
28. Celecoxib: A review of its use in osteoarthritis, rheumatoid arthritis and acute pain
29. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial
30. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis
31. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip
32. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis
33. New pharmacological strategies for pain relief
34. Nonsteroidal antiinflammatory drugs in perisurgical pain management. Mechanisms of action and rationale for optimum use
35. The mechanisms of action of NSAIDs in analgesia
36. Spinal actions of nonsteroidal anti-inflammatory drugs
37. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation
38. Analyses of the effects of cyclooxygenase (COX)-1 and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective inhibitor
39. Analgesic activity of the novel COX-2 preferring NSAID, meloxicam, in mono-arthritic rats: Central and peripheral components
40. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain
41. Pain management in osteoarthritis: The role of COX-2 inhibitors
42. The optimal analgesic dose of rofecoxib: Overview of six randomized controlled trials
43. Superior efficacy of rofecoxib compared to codeine with acetaminophen for the treatment of acute pain
44. Efficacy of single-dose and multidose rofecoxib in the treatment of post-orthopedic surgery pain
45. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: A randomized controlled trial
46. Involvement of cyclooxygenase-2 in LPS-induced fever and regulation of its mRNA by LPS in the brain
47. Possible role of cyclooxygenase-2 in the brain vasculature in febrile response
48. Inhibition of brain cyclooxygenase-2 activity and the antipyretic action of nimesulide
49. Induction of cyclooxygenase-2 in the brain by cytokines
50. Expression and regulation of cyclooxygenase-2 in rat microglia
51. Inhibition of cyclooxygenase-2 protects motor neurons in an organotypic model of amyotrophic lateral sclerosis
52. Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis
53. Alzheimer's disease and inflammation: A review of cellular and therapeutic mechanisms
54. Anti-inflammatory drugs: A hope for Alzheimer's disease?
55. Neuroinflammatory signaling upregulation in Alzheimer's disease
56. Do nonsteroidal anti-inflammatory drugs decrease the risk of Alzheimer's disease? The Rotterdam study
57. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies
58. Risk of Alzheimer disease and duration of NSAID use
59. The non-steroidal anti-inflammatory drug tepoxalin inhibits interleukin-6 and alpha1-anti-chymotrypsin synthesis in astrocytes by preventing degradation of IkappaB-alpha
60. Inflammatory mechanisms in Alzheimer's disease: Inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists
61. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs
62. Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: A current appraisal
63. Elevated CSF prostaglandin E2 levels in patients with probable AD
64. Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease
65. Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease
66. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain
67. Interleukin-1beta induces cyclooxygenase-2 and prostaglandin E(2) synthesis in human neuroblastoma cells: Involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB
68. New functions for COX-2 in health and disease: Report of "The Third International Workshop on Cox-2"
69. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain
70. Cyclooxygenase-1 in human Alzheimer and control brain: Quantitative analysis of expression by microglia and CA3 hippocampal neurons
71. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative study
72. Clinical trial of indomethacin in Alzheimer's disease
73. Cyclooxygenase-2: Molecular biology, pharmacology, and neurobiology
74. Toxicity of human THP-1 monocytic cells towards neuron-like cells is reduced by non-steroidal anti-inflammatory drugs (NSAIDs)
75. Cerebromicrovascular pathology in Alzheimer's disease compared to normal aging
76. Amyloid precursor protein and amyloid beta peptide in human platelets: Role of cyclooxygenase and protein kinase C
77. Prostaglandins and the kidney
78. The role of prostaglandins in the control of renal function: Renal effects of nonsteroidal anti-inflammatory drugs
79. Prostaglandin receptors: Their role in regulating renal function
80. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction
81. Cloning, expression and regulation of rabbit cyclooxygenase-2 in renal medullary interstitial cells
82. Effect of prostaglandin E2 on chloride transport across the rabbit thick ascending limb of Henle
83. Functional and molecular aspects of renal prostaglandin receptors
84. Differential localization of prostaglandin E receptor subtypes in human kidney
85. G protein-coupled prostanoid receptors and the kidney
86. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II
87. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse
88. Postnatal development and progression of renal dysplasia in cyclooxygenase-2 null mice
89. Are selective COX-2 inhibitors nephrotoxic?
90. 2 receptor EP2 in rat and human mesangioproliferative glomerulonephritis
91. Regulatory interactions between inducible nitric oxide synthase and eicosanoids in glomerular immune injury
92. NSAIDs, gastrointestinal injury and cytoprotection
93. NSAID gastropathy. A new understanding
94. Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1
95. Role of intestinal epithelial cells in the host secretory response to infection by invasive bacteria. Bacterial entry induces epithelial prostaglandin H synthase-2 expression and prostaglandin E2 and F2 alpha production
96. Expression of cyclooxygenase 1 and 2 by human gastric endothelial cells
97. Involvement of cyclooxygenase (COX)-2 products in acceleration of ulcer healing by gastrin and hepatocyte growth factor
98. Induction of cyclooxygenase-2 in rat gastric mucosa by rebamipide, a mucoprotective agent
99. Biologic effects of nonsteroidal anti-inflammatory drugs
100. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
101. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS Study: A randomized controlled trial
102. Aspirin use and reduced risk of fatal colon cancer
103. Aspirin use and risk of fatal cancer
104. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals
105. Aspirin and the risk of colorectal cancer in women
106. Colorectal cancer and nonsteroidal anti-inflammatory drugs
107. The role of cyclooxygenases in inflammation, cancer and development
108. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
109. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas
110. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer
111. Expression of cyclooxygenase-1 and -2 in human colorectal cancer
112. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: Lack of correlation between in vitro and in vivo models
113. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2
114. Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis
115. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis
116. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway
117. Sulfone metabolite of sulindac inhibits mammary carcinogenesis
118. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction
119. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs
120. Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells
121. The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention
122. Δ716 knockout mice by inhibition of prostaglandin endoperoxide synthase-2 (COX-2)
123. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis
124. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor
125. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
126. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease
127. Role of cyclooxygenases in angiogenesis
128. The contributions of cyclooxygenase-2 to tumor angiogenesis
129. Host cyclooxygenase-2 modulates carcinoma growth
130. 2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis
131. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing
132. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
133. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer
134. Expression of cyclooxygenase-2 in human lung carcinoma
135. Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-δ in human endometrial adenocarcinoma
136. Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy
137. Celecoxib inhibits N-butyl-N-(4hydroxybutyl)-nitrosamine-indu ced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats
138. The role of cyclooxygenase enzymes in the growth of human gall bladder cancer cells
139. COX-2 expression is induced by UVB exposure in human skin: Implications for the development of skin cancer
140. Expression of cyclooxygenase 2 in human malignant melanoma
141. Inhibition of cyclooxygenase-2 expression. An approach to preventing head and neck cancer
142. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis
143. Cyclooxygenase-2 expression in human esophageal carcinoma
144. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus
145. Eicosanoids and the gastrointestinal tract
146. Cyclo-oxygenase-2 inhibitors ameliorate the severity of experimental colitis in rats
147. Lack of beneficial effect of COX-2 inhibitors in an experimental model of colitis
148. Cyclooxygenase-2-derived prostaglandin D(2) is an early anti-inflammatory signal in experimental colitis
149. Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation
150. Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease
151. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease
152. Cellular localization of cyclooxygenase isozymes in Crohn's disease and colorectal cancer
153. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: A case-control study